Methylphenidate in Treating Patients With Melanoma

Completed · Phase 3

Conditions studied: Fatigue, Unspecified Adult Solid Tumor, Protocol Specific

In brief

RATIONALE: Methylphenidate may relieve some of the side effects of chemotherapy in patients with melanoma. It is not known whether receiving methylphenidate is more effective than receiving no further therapy in treating patients with melanoma. PURPOSE: Randomized phase III trial to determine if methylphenidate is more effective than no further therapy for the relief of fatigue and drowsiness in treating patients with melanoma who have received high-dose interferon alfa for 8-24 weeks.

Key facts

Study ID
NCT00003266
Run by
Eastern Cooperative Oncology Group
People needed
200
Starts
1999-10-12
Last updated by the study team
2023-06-18

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.